Femasys Inc. (NASDAQ:FEMY) Stock Position Raised by Geode Capital Management LLC

Geode Capital Management LLC lifted its holdings in shares of Femasys Inc. (NASDAQ:FEMY) by 9.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 206,483 shares of the company’s stock after buying an additional 17,473 shares during the period. Geode Capital Management LLC owned 0.90% of Femasys worth $229,000 at the end of the most recent reporting period.

Separately, XTX Topco Ltd boosted its stake in Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the period. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

Femasys Stock Down 2.8 %

FEMY stock opened at $1.05 on Tuesday. Femasys Inc. has a 12 month low of $0.73 and a 12 month high of $2.40. The firm has a market cap of $24.04 million, a PE ratio of -1.30 and a beta of -2.82. The firm has a 50 day simple moving average of $1.09 and a 200 day simple moving average of $1.12. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26.

Femasys (NASDAQ:FEMY) last released its earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The business had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. Equities research analysts forecast that Femasys Inc. will post -0.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on FEMY shares. Chardan Capital reduced their target price on shares of Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Femasys in a research note on Tuesday, December 3rd.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.